vs
EXACT SCIENCES CORP（EXAS）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是EXACT SCIENCES CORP的1.7倍（$1.5B vs $878.4M），RXO, Inc.净利率更高（-3.1% vs -9.8%，领先6.7%），EXACT SCIENCES CORP同比增速更快（23.1% vs -11.9%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
EXAS vs RXO — 直观对比
营收规模更大
RXO
是对方的1.7倍
$878.4M
营收增速更快
EXAS
高出35.0%
-11.9%
净利率更高
RXO
高出6.7%
-9.8%
自由现金流更多
EXAS
多$129.4M
$-9.0M
两年增速更快
RXO
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.5B |
| 净利润 | $-86.0M | $-46.0M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | -2.9% |
| 净利率 | -9.8% | -3.1% |
| 营收同比 | 23.1% | -11.9% |
| 净利润同比 | 90.1% | -84.0% |
| 每股收益（稀释后） | $-0.45 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRXO
| Q4 25 | $878.4M | $1.5B | ||
| Q3 25 | $850.7M | $1.4B | ||
| Q2 25 | $811.1M | $1.4B | ||
| Q1 25 | $706.8M | $1.4B | ||
| Q4 24 | $713.4M | $1.7B | ||
| Q3 24 | $708.7M | $1.0B | ||
| Q2 24 | $699.3M | $930.0M | ||
| Q1 24 | $637.5M | $913.0M |
净利润EXASRXO
| Q4 25 | $-86.0M | $-46.0M | ||
| Q3 25 | $-19.6M | $-14.0M | ||
| Q2 25 | $-1.2M | $-9.0M | ||
| Q1 25 | $-101.2M | $-31.0M | ||
| Q4 24 | $-864.6M | $-25.0M | ||
| Q3 24 | $-38.2M | $-243.0M | ||
| Q2 24 | $-15.8M | $-7.0M | ||
| Q1 24 | $-110.2M | $-15.0M |
毛利率EXASRXO
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASRXO
| Q4 25 | -9.4% | -2.9% | ||
| Q3 25 | -3.0% | -0.5% | ||
| Q2 25 | -0.3% | — | ||
| Q1 25 | -13.6% | -2.1% | ||
| Q4 24 | -122.8% | -1.4% | ||
| Q3 24 | -5.6% | -1.9% | ||
| Q2 24 | -3.8% | — | ||
| Q1 24 | -16.7% | -1.3% |
净利率EXASRXO
| Q4 25 | -9.8% | -3.1% | ||
| Q3 25 | -2.3% | -1.0% | ||
| Q2 25 | -0.1% | -0.6% | ||
| Q1 25 | -14.3% | -2.2% | ||
| Q4 24 | -121.2% | -1.5% | ||
| Q3 24 | -5.4% | -23.4% | ||
| Q2 24 | -2.3% | -0.8% | ||
| Q1 24 | -17.3% | -1.6% |
每股收益（稀释后）EXASRXO
| Q4 25 | $-0.45 | $-0.28 | ||
| Q3 25 | $-0.10 | $-0.08 | ||
| Q2 25 | $-0.01 | $-0.05 | ||
| Q1 25 | $-0.54 | $-0.18 | ||
| Q4 24 | $-4.69 | $-0.17 | ||
| Q3 24 | $-0.21 | $-1.81 | ||
| Q2 24 | $-0.09 | $-0.06 | ||
| Q1 24 | $-0.60 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $17.0M |
| 总债务越低越好 | — | $387.0M |
| 股东权益账面价值 | $2.4B | $1.5B |
| 总资产 | $5.9B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资EXASRXO
| Q4 25 | $964.7M | $17.0M | ||
| Q3 25 | $1.0B | $25.0M | ||
| Q2 25 | $858.4M | $18.0M | ||
| Q1 25 | $786.2M | $16.0M | ||
| Q4 24 | $1.0B | $35.0M | ||
| Q3 24 | $1.0B | $55.0M | ||
| Q2 24 | $946.8M | $7.0M | ||
| Q1 24 | $652.1M | $7.0M |
总债务EXASRXO
| Q4 25 | — | $387.0M | ||
| Q3 25 | — | $387.0M | ||
| Q2 25 | — | $387.0M | ||
| Q1 25 | — | $387.0M | ||
| Q4 24 | — | $351.0M | ||
| Q3 24 | — | $352.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $351.0M |
股东权益EXASRXO
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.5B | $1.6B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.4B | $1.6B | ||
| Q4 24 | $2.4B | $1.6B | ||
| Q3 24 | $3.2B | $1.7B | ||
| Q2 24 | $3.2B | $579.0M | ||
| Q1 24 | $3.1B | $582.0M |
总资产EXASRXO
| Q4 25 | $5.9B | $3.3B | ||
| Q3 25 | $5.9B | $3.2B | ||
| Q2 25 | $5.8B | $3.2B | ||
| Q1 25 | $5.7B | $3.3B | ||
| Q4 24 | $5.9B | $3.4B | ||
| Q3 24 | $6.7B | $3.4B | ||
| Q2 24 | $6.7B | $1.8B | ||
| Q1 24 | $6.4B | $1.8B |
负债/权益比EXASRXO
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $-9.0M |
| 自由现金流率自由现金流/营收 | 13.7% | -0.6% |
| 资本支出强度资本支出/营收 | 3.6% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $-8.0M |
8季度趋势，按日历期对齐
经营现金流EXASRXO
| Q4 25 | $151.7M | $7.0M | ||
| Q3 25 | $219.9M | $23.0M | ||
| Q2 25 | $89.0M | $23.0M | ||
| Q1 25 | $30.8M | $-2.0M | ||
| Q4 24 | $47.1M | $-7.0M | ||
| Q3 24 | $138.7M | $-7.0M | ||
| Q2 24 | $107.1M | $-5.0M | ||
| Q1 24 | $-82.3M | $7.0M |
自由现金流EXASRXO
| Q4 25 | $120.4M | $-9.0M | ||
| Q3 25 | $190.0M | $9.0M | ||
| Q2 25 | $46.7M | $9.0M | ||
| Q1 25 | $-365.0K | $-17.0M | ||
| Q4 24 | $10.7M | $-19.0M | ||
| Q3 24 | $112.6M | $-18.0M | ||
| Q2 24 | $71.2M | $-16.0M | ||
| Q1 24 | $-120.0M | $-4.0M |
自由现金流率EXASRXO
| Q4 25 | 13.7% | -0.6% | ||
| Q3 25 | 22.3% | 0.6% | ||
| Q2 25 | 5.8% | 0.6% | ||
| Q1 25 | -0.1% | -1.2% | ||
| Q4 24 | 1.5% | -1.1% | ||
| Q3 24 | 15.9% | -1.7% | ||
| Q2 24 | 10.2% | -1.7% | ||
| Q1 24 | -18.8% | -0.4% |
资本支出强度EXASRXO
| Q4 25 | 3.6% | 1.1% | ||
| Q3 25 | 3.5% | 1.0% | ||
| Q2 25 | 5.2% | 1.0% | ||
| Q1 25 | 4.4% | 1.0% | ||
| Q4 24 | 5.1% | 0.7% | ||
| Q3 24 | 3.7% | 1.1% | ||
| Q2 24 | 5.1% | 1.2% | ||
| Q1 24 | 5.9% | 1.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
